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Abstract: From 2-aminonorbornene hydroxamic acids, a simple and efficient method for the
preparation of pyrrolo[1,2-a]pyrimidine enantiomers is reported. The synthesis is based on domino
ring-closure followed by microwave-induced retro Diels-Alder (RDA) protocols, where the chirality
of the desired products is transferred from norbornene derivatives. The stereochemistry of the
synthesized compounds was proven by X-ray crystallography. The absolute configuration of the
product is determined by the configuration of the starting amino hydroxamic acid.
Keywords: domino reactions; hydroxamic acid; microwave chemistry; N-heterocycles; retro Diels-Alder
reaction
1. Introduction
The first hydroxamic acid (oxalohydroxamic acid [1]) was discovered by Lossen as early as 1869.
However, hydroxamic acids attracted further attention at the beginning of the 1980s because of their
bioactivity [2]. Their pharmacological properties are related to their ability to scavenge metal ions [3].
In addition, they are able to generate nitric oxide [3–5] in living systems. In this way, they can act as
antimicrobial [6–9], antitumour [6,10], antihypertensive [11], anti-inflammatory [6,12], and neuroleptic
agents, among others [3,13].
According to the literature data, aromatic hydroxamic acids are useful compounds [14–23].
However, only limited information is available about their reactions [24,25] and, in particular, about
the properties of alicyclic derivatives [26,27].
Though the hydroxamic acid moiety is an important key pharmacophore in most cases, it is usually
built up just in the last step of the synthesis [28–30]. Previously, we have examined the reactivity and
stereoselectivity of the domino reaction of 2-aminonorbornene hydroxamic acids with 2-formylbenzoic
acid and 2,3-dimethoxy-6-formylbenzoic acid to form new isoindolo[2,1-a]quinazolines and
pyrimido[2,1-a]isoindoles [31].
Focusing on the biological potential of fused quinazolinones, and continuing our work on the
synthesis of novel N-heterocycles, herein, we report the synthesis of a new series of pyrrolo[1,2-a]
quinazolinones and pyrrolo[1,2-a]pyrimidines starting from hydroxamic acids. Pyrroloquinazolines
and pyrrolopyrimidines are important heterocyclic ring systems that occur as a core structure in a
variety of naturally occurring alkaloids and synthetic compounds. Pyrrolo[1,2-a]quinazolines are
tricyclic compounds with great potential and combine the quinazoline substructure, a privileged
structure in medicinal chemistry, with a pyrrole [32]. Their synthetic methods are rather scarce but the
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past five years have brought efficient new synthetic strategies which could lead to an increased interest
in pyrrolo[1,2-a]quinazolines in the near future, mainly for their potential applications in medicinal
chemistry [33–38].
Pyrrolopyrimidines display a broad applicability in medicinal chemistry exhibiting antimicrobial [39–43],
antitumour [44–58], antiasthmatic [59], antihypertensive [60], and anti-inflammatory [61] activities.
Several method have been developed for synthesizing pyrrolopyrimidines in the last few years [62–70].
We recently reported an efficient and convenient procedure for the preparation of pyrrolo[1,2-a]
pyrimidines starting from 2-aminonorbornene hydroxamic acids [31]. The synthesis was based on the
domino ring-closure reaction of hydroxamic acids with oxocarboxylic acids, followed by RDA reaction
of the tetracyclic intermediates.
The present target derivatives were planned to be prepared by a two-step strategy: first, the
domino ring-closure reaction of diendo- and diexo-2-aminonorbornene hydroxamic acid with levulinic
acid and α-ketoglutaric acid was carried out, followed by the second step involving the RDA reaction
of the formed tetracycles by the loss of cyclopentadiene.
Domino reactions with hydroxamic acids are not well-documented in the literature. There are
examples for the main simple ring-closures with cyclic anhydrides [19], aldehydes [71], sodium
nitrite [20], carbon disulfide [72], formic acid, or acetyl chloride [17].
Our present aim was (i) to examine the domino ring-closure reaction of diendo- and
diexo-aminonorbornene hydroxamic acids 1 and 2, (ii) to develop the retro Diels-Alder reaction of
the tetracyclic heterocycles formed, and to extend this methodology to obtain novel racemic and
enantiomeric pyrrolo[1,2-a]pyrimidine derivatives.
2. Results and Discussion
Racemic diendo- and diexo-2-aminonorbornene hydroxamic acids (±)-1 and (±)-2 were prepared
from the appropriate ester bases with aqueous hydroxylamine solution according to an earlier
procedure [31]. The enantiomers of 2-aminonorbornene hydroxamic acid (+)-1, (–)-1, (+)-2, and (–)-2
were prepared from racemic esters via diastereomeric salt formation with O,O’-di-p-toluoyl-tartaric
acid (DPTTA) and O,O’-di-benzoyl-tartaric acid (DBTA) as previously described [31].
In the optimization experiments of the domino reactions of levulinic acid and α-ketoglutaric
acid with racemic diendo-2-aminonorbornene hydroxamic acid (±)-1 and diexo-2-aminonorbornene
hydroxamic acid (±)-2, conventional heating or microwave irradiation was applied. The reaction time
was significantly shorter in the microwave reactor: the best results were achieved in ethanol stirred at
100 ◦C for 1 h.
In the domino reaction of 1 and 2 with levulinic acid and α-ketoglutaric acid, the first Schiff base
A is produced, which undergoes a ring-closure reaction to produce the quinazoline epimers B and C,
which are formed from A through a ring-chain tautomerism. The second ring-closure involves epimers
B and C that yields compounds D and E (Scheme 1) [68].
Molecules 2017, 22, 613 2 of 13 
 
years have brough  efficient new synthe c strategies which could le d to an increased interest in 
pyrrolo[1,2-a]quinazolines in the near future, mainly for their potential applications in medicinal 
chemistry [33–38]. 
Pyrrolopyrimidines display a broad applicability in medicinal chemistry exhibiting antimicrobial 
[39–43], antitumour [44–58], antiasthmatic [59], antihypertensive [60], and anti-inflammatory [61] 
activities. Several method have been developed for synthesizing pyrrolopyrimidines in the last few 
years [62–70]. 
We recently reported n efficient and co v nient procedure for the preparation of pyrrolo[1,2-a] 
pyrimidines starting from 2-aminonorbornene hydroxamic acids [31]. The synthes s was based on 
the domino ring-closure reaction of hydroxamic acids with oxocarboxylic acids, followed by RDA 
reaction of the tetracyclic intermediates. 
The present target derivatives were planned to be prepared by a two-step strategy: first, the 
domino ring-closure reaction of diendo- and diexo-2-aminonorbornene hydroxamic acid with levulinic 
acid and α-ketoglutaric acid was carried out, followed by the second step involving the RDA reaction 
of the formed tetracycles by the loss of cyclopentadiene. 
Domi o reactions with hydroxamic acids ar  not well-documented in the literature. Ther  are 
examples for the main simple ring-closures with cyclic anhydrides [19], aldehydes [71], sodium  
nitrite [20], carbon disulfide [72], formic acid, or acetyl chloride [17]. 
Our present aim was (i) to examine the domino ring-closure reaction of diendo- and diexo-
aminonorbornene hydroxamic acids 1 and 2, (ii) to develop the retro Diels-Alder reaction of the 
tetracyclic heterocycles formed, and to extend this methodology to obtain novel racemic and 
enantiomeric pyrrolo[1,2-a]pyrimidine derivatives. 
2. Results and Discussion 
Racemic di ndo- and diexo-2-aminonorb rnene hydroxamic acids (±)-1 and (±)-2 were prepared 
from the appropriate ester bases with aqueous hydroxylamine solution according to an earlier 
procedure [31]. The enantiomers of 2-aminonorbornene hydroxamic acid (+)-1, (–)-1, (+)-2, and (–)-2 
were prepared from racemic esters via diastereomeric salt formation with O,O’-di-p-toluoyl-tartaric 
acid (DPTTA) and O,O’-di-benzoyl-tartaric acid (DBTA) as previously described [31]. 
In the optimization experiments of the domino reactions of levulinic acid and α-ketoglutaric acid 
with racemic diendo-2-aminonorbornene hydroxamic acid (±)-1 and diexo-2-aminonorbornene 
hydroxamic acid (±)-2, conventional heating or microwave ir adiation was appl d. The r action time 
was significantly shorter in the microwave reactor: the best results were achieved in ethanol stirred 
at 100 °C for 1 h. 
In the domino reaction of 1 and 2 with levulinic acid and α-ketoglutaric acid, the first Schiff base 
A is produced, which undergoes a ring-closure reaction to produce the quinazoline epimers B and C, 
which are formed from A through a ring-chain tautomerism. The second ring-closure involves 
epimers B and C that yields compounds D and E (Scheme 1) [68]. 
 
Scheme 1. The domino reaction pathway. Scheme 1. The domino reaction pathway.
Molecules 2017, 22, 613 3 of 13
The NMR spectra revealed the formation of two diastereomers of the methanopyrrolo[1,2-a]
quinazolines D and E (Scheme 1). Unfortunately, we were not able to separate the diastereomers
by column chromatography despite the use of a range of eluent combinations (for example: EtOAc,
EtOAc/hexane = 1:1, EtOAc/MeOH = 9:1, CHCl3/MeOH = 9:1, or toluene/MeOH = 4:1). Fortunately,
after derivatization with diazomethane, the diastereomers (±)-3a, (±)-3b and (±)-4a, (±)-4b could be
easily separated by column chromatography eluted with EtOAc (Scheme 2).
The stereochemistry of (±)-3a and (±)-4b was confirmed by X-ray diffraction analysis. The relative
configuration of the COOCH3 group at C-3a and the bridgehead hydrogens of C-5a and C-9a have the
same steric orientation in the (±)-3a and (±)-4b tetracyclic derivatives (Figures 1 and 2).
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In order to produce racemic pyrrolo[1,2-a]pyrimidi 5, the retro Diels-Alder reaction of the
methanopyrrolo[1,2-a]quinazoline derivatives was examined in the microwave reactor under varied
conditions. The best results for the cycloreversion were achieved in 1,2-dichlorobenzene (DCB) at
250 ◦C (20 mi ).
The synthetic method describe abov was extend d for the preparation f the enanti merically
pure substances, via the protocol described for the racemic substances. The domino ring-closure
reaction of diendo-2-aminonorbornene hydroxamic acid enantiomer (+)-1 resulted in (–)-3a and (–)-3b,
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while that with the diexo-2-aminonorbornene hydroxamic acid enantiomer (+)-2 resulted in epimers
(–)-4a and (+)-4b. After their separation, the RDA reactions of tetracycles could easily be achieved,
resulting in pyrrolo[1,2-a]pyrimidine (+)-5 and (–)-5 (Scheme 2).
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We attempted to use the same methodology to synthesize racemic 8. In this case, however, the
ring-closure reaction with levulinic acid resulted in only a small quantity of the minor diastereomers
(±)-6b and (±)-7b, which could not be isolated. The stereochemistry of (±)-6a was confirmed by X-ray
diffraction analysis. The relative configuration of the CH3 group at the C-3a asymmetric centre and the
bridgehead hydrogens of C-5a and C-9a have the same steric orientation in (±)-6a (Figure 3).
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We selected an economically better approach for the synthesis of (+)-8 and (–)-8. Namely, we
carried out the cycloreversions of the major methanopyrrolo[1,2-a]quinazoline derivatives (+)-6a,
(–)-6a, (+)-7a, and (–)-7a and isolated the pyrrolo[1,2-a]pyrimidines (+)-8 and (–)-8 in 55–57% yields
(see Schemes 3 and 4).
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Scheme 4. Synthesis of (+)-8: (i) levulinic acid, 1 h, 100 ◦C, EtOH, MW; (ii) MeOH, diazomethane/Et2O,
r.t.; (iii) isolation of major (–)-6a, (–)-7a) epimers by column chromatography (eluent: EtOAc:MeOH
= 9:1); (iv) RDA reaction of major epimers: MW, 220 ◦C, 20 min, 300 W, (v) column chromatography
(eluent: EtOAc:MeOH =9:1).
The absolute configuration of the ewly built asymmetric centre of (+)-7a and (–)-7a was
determined by chemical rr lation: the abs lute configurations of the st rting 2-amino orbor ene
hydroxamic acids, and the r lative configuration of (±)-6a from the X-ray diffraction analysis was
known. When (+)-7a was heated under the RDA reaction conditions, (–)-8 was gained. In addition,
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the RDA product of (+)-6a also afforded (–)-8. In contrast, when (–)-7a and (–)-6a were treated under
the RDA reaction conditions, (+)-8 was formed. The NMR and HPLC data (retention times: (–)-8:
41.91 min, opposite enantiomer (+)-8: 34.19 min) and comparison of the optical rotations revealed
that the final compound was identical to that of (R)-1-methoxy-8a-methyl-1,7,8,8a-tetrahydropyrrolo
[1,2-a]pyrimidine-2,6-dione (–)-8. Since this asymmetric centre was not affected during the RDA
reaction, these results allow for the assumption that the absolute configuration of position 3a of (+)-7a
is R, and that of (–)-7a is S.
3. Materials and Methods
3.1. General Methods
1H-NMR spectra were recorded at 400.13 MHz or 600.20 MHz and the 13C-NMR spectra were
recorded at 100.62 MHz or 150.92 MHz in CDCl3 at ambient temperature, with a Bruker AM 400 or
Bruker AV 600 spectrometer (Bruker Biospin, Karlsruhe, Germany). Chemical shifts are given in δ
(ppm) relative to TMS as the internal standard. Microwave-promoted reactions were performed in
sealed reaction vials (10 mL) in a microwave (CEM, Discover SP) cavity (CEM Corporation, Matthwes,
NC, USA). Optical rotations were measured with a Perkin-Elmer 341 polarimeter (Perkin Elmer,
Shelton, CT, USA). Mass spectra were recorded with a Micromass Q-TOF Premier mass spectrometer
(Waters Corporation, Milford, MA, USA). Melting points were measured with a Hinotek-X4 micro
melting point apparatus (Hinotek, Ningbo, China) and are uncorrected. Racemic 2-aminonorbornene
hydroxamic acids (±)-1 and (±)-2 and enantiomeric 2-aminonorbornene hydroxamic acids (+)-1, (–)-1,
(+)-2, and (–)-2 were prepared by a literature method [31]. The ee values of (+)-1, (–)-1, (+)-2, and
(–)-2 were determined by HPLC by a literature method [73]. CCDC-1508562-1508564 contains the
supplementary crystallographic data for this paper. These data can be obtained free of charge from
The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.
The ee values of (–)-3a, (–)-3b, (–)-4a, and (+)-4b were determined by HPLC using a
Chiralcel-OD-H column (Daicel corporation, Tokyo, Japan). The analytical conditions were as follows:
eluent: a mixture of hexane and EtOH (75:25) with 0.1% diethylamine, flow rate: 0.4 mL·min−1,
detection at 220 nm retention times: (−)-3a: 18.82 min (antipode: 22.16 min), (–)-3b: 19.84 min
(antipode: 24.23 min), (+)-4a: 20.74 min (antipode: 17.48 min), (–)-4b: 24.22 min (antipode: 20.97 min).
(+)-6a, (–)-6a, (+)-7a, and (–)-7a were determined using a Phenomenex-IA column (Phenomenex,
Torrance, CA, USA) eluted by a mixture of hexane and IPA (70:30), flow rate: 0.4 mL·min−1, detection
at 220 nm, retention times: (+)-6a: 32.94 min, (–)-6a: 39.46 min, (+)-7a: 31.39 min, (–)-7a: 35.39 min).
The ee values of the final products of (+)-5, (–)-5, (+)-8, and (–)-8 were determined by HPLC using
a Phenomenex-IA column. The analytical conditions were as follows: eluent: a mixture of hexane
and IPA (70:30), flow rate: 0.4 mL·min−1, detection at 220 nm, retention times: (+)-5: 47.97 min, (–)-5:
57.79 min, (+)-8: 34.19 min, (–)-8: 41.91 min.
1H-NMR and 13C-NMR spectra of compounds (–)-3a, (–)-3b, (–)-4a, (+)-4b, (+)-5 (+)-6a, (+)-7a
and (+)-8, HPLC chromatogram of compounds (±)-5, (–)-5, (+)-5 (±)-8 (–)-8, (+)-8, and table for X-ray
crystallography data for (±)-3a, (±)-4a and (±)-6a are available in the Supplementary materials.
3.2. Synthesis of New Compounds
3.2.1. Synthesis of Methanopyrrolo[1,2-a]quinazoline Derivatives (–)-3a, (–)-3b, (–)-4a, and (+)-4b
A mixture of 2-aminonorbornene hydroxamic acid (+)-1 or (+)-2 (336 mg, 2 mmol), and
α-ketoglutaric acid (292 mg, 2 mmol) was dissolved in 6 mL EtOH in a 10 mL pressurized reaction vial
and the solution was stirred at 100 ◦C for 1 h at max 300 W microwave irradiation. Then the reaction
mixture was evaporated to dryness and the crude product was crystallized from Et2O. The crystals
isolated were dissolved in MeOH and a diazomethane/Et2O mixture was added dropwise to the
solution at ambient temperature and was stirred for 30 min. The reaction was followed by TLC.
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(Diazomethane is a very harmful and hazardous reagent and must be handled with caution! This
reaction should be performed in a well-ventilated hood!) The solvent was then removed by evaporation
and the residue was dissolved in 2 mL EtOAc and transferred to a silica gel column (Merck, Darmstadt,
Germany) and eluted with EtOAc. The product was crystallized from iPr2O to produce white crystals.
Methyl (3aS,5aS,6R,9S,9aR)-4-methoxy-1,5-dioxo-1,2,3,3a,4,5,5a,6,9a-decahydro-6,9-methanopyrrolo[1,2-a]
quinazoline-3a-carboxylate [(–)-3a)]: White crystals (39% yield), m.p. 125–128 ◦C, [α]20D = –92.5 (c = 0.33,
EtOH), ee 87%, 1H-NMR (400 MHz, CDCl3, 30 ◦C): 1.36–1.38 (m, 1H, 11-H), 1.58–1.60 (m, 1H, 11-H),
2.13–2.21 (m, 1H, CH2), 2.45–2.51 (m, 1H, CH2), 2.58–2.74 (m, 2H, CH2), 3.09–3.12 (m, 1H, 5a-H), 3.43
(m, 1H, 9-H), 3.82 (s, 3H, COOCH3), 3.85 (s, 3H, OCH3), 3.93–3.95 (m, 1H, 9a-H), 4.06 (m, 1H, 6-H),
6.07–6.09 (m, 1H, 8-H), 6.20–6.22 (m, 1H, 7-H), 13C-NMR (100 MHz, CDCl3, 30 ◦C): δ = 28.1, 30.1, 41.1,
46.6, 46.9, 46.9, 47.3, 54.0, 54.6, 65.3, 82.3, 135.7, 136.1, 170.0, 172.3, 173.9, HRMS calcd. for [M + H+]
m/z = 307.1294, measured: m/z = 307.1288.
Methyl (3aR,5aS,6R,9S,9aR)-4-methoxy-1,5-dioxo-1,2,3,3a,4,5a,6,9a-decahydro-6,9-methanopyrrolo[1,2-a]
quinazoline-3a-carboxylate [(–)-3b)]: White crystals (44% yield), m.p. 170–172 ◦C, [α]20D = −3.8 (c = 0.30,
EtOH), ee 97%, 1H-NMR (600 MHz, CDCl3, 30 ◦C): 1.44–1.45 (m, 1H, 11-H), 1.56–1.63 (m, 1H, 11-H),
2.24–2.30 (m, 1H, CH2), 2.46–2.50 (m, 2H, CH2), 2.79–2.85 (m, 1H, CH2), 3.25–3.28 (m, 2H, 5a-H, 9-H),
3.42 (m, 1H, 6-H), 3.78 (s, 3H, COOCH3), 3.89 (s, 3H, OCH3), 4.68–4.69 (m, 1H, 9a-H), 5.73–5.75 (m, 1H,
8-H), 6.19–6.20 (m, 1H, 7-H), 13C-NMR (100 MHz, CDCl3, 30 ◦C): δ = 29.2, 32.1, 45.1, 46.3, 47.2, 48.9,
52.9, 53.1, 64.3, 81.6, 134.2, 138.6, 168.4, 170.3, 174.9, HRMS calcd. for [M + H+] m/z = 307.1294, found
m/z = 307.1288.
Methyl (3aS,5aR,6R,9S,9aS)-4-methoxy-1,5-dioxo-1,2,3,3a,4,5a,6,9a-decahydro-6,9-methanopyrrolo[1,2-a]
quinazoline-3a-carboxylate [(–)-4a)]: White crystals, (44% yield), m.p. 125–128 ◦C, [α]20D = −64 (c = 0.30,
EtOH), ee 97% 1H-NMR (600 MHz, CDCl3, 30 ◦C): 1.39–1.40 (m, 1H, 11-H), 1.49–1.50 (m, 1H, 11-H),
2.40–2.56 (m, 3H, CH2), 2.65–2.81 (m, 3H, CH2, 5a-H, 9-H), 3.34 (m, 1H, 6-H), 3.84 (s, 3H, COOCH3),
4.02 (s, 3H, OCH3), 4.15 (m, 1H, 9a-H), 6.23–6.25 (m, 1H, 7-H), 6.31–6.33 (m, 1H, 8-H), 13C-NMR (150
MHz, CDCl3, 30 ◦C): δ = 29.1, 30.9, 44.4, 44.8, 46.9, 47.5, 51.9, 53.4, 64.0, 81.6, 137.6, 138.4, 167.7, 170.9,
173.9, HRMS calcd. for [M + H+] m/z = 307.1294, found m/z = 307.1288.
Methyl (3aR,5aR,6R,9S,9aS)-4-methoxy-1,5-dioxo-1,2,3,3a,4,5a,6,9a-decahydro-6,9-methanopyrrolo[1,2-a]
quinazoline-3a-carboxylate [(+)-4b]: White crystals, (39% yield), m.p. 170–172 ◦C, [α]20D = + 6.5 (c = 0.33,
EtOH), ee 81%, 1H-NMR (600 MHz, CDCl3, 30 ◦C): 1.51–1.52 (m, 2H, 11-H), 2.25–2.30 (m, 1H, CH2),
2.58–2.82 (m, 4H, CH2, 5a-H), 3.35 (m, 1H, 9-H), 3.39–3.40 (m, 1H, 6-H), 3.81 (s, 3H, COOCH3), 3.94 (s,
3H, OCH3), 3.99 (m, 1H, 9a-H), 6.17–6.19 (m, 1H, 7-H), 6.33–6.34 (m, 1H, 8-H), 13C-NMR (150 MHz,
CDCl3, 30 ◦C): δ = 27.9, 30.1, 43.7, 44.6, 46.6, 47.7, 53.7, 54.3, 65.0, 82.0, 135.7, 138.6, 169.4, 173.2, 174.1,
HRMS calcd. for [M + H+] m/z = 307.1294, found m/z = 307.1288.
3.2.2. Synthesis of Pyrrolo[1,2-a]pyrimidines (+)-5 and (–)-5
Tetracyclic compound (–)-3a, (–)-4a, or (–)-3b and (+)-4b (50 mg, 0.16 mmol,) was dissolved
in 2 mL DCB in a 10 mL sealed reaction vial. The solution was stirred at 250 ◦C for 20 min at
max 300 W microwave irradiation. Then the solvent was evaporated, the residue was dissolved in
2 mL EtOAc/MeOH = 9:1, and was purified by column chromatography on silica gel eluted by
EtOAc/MeOH = 9:1. The product was crystallized from iPr2O to produce white crystals.
Methyl (R)-1-methoxy-2,6-dioxo-1,2,6,7,8,8a-hexahydropyrrolo[1,2-a]pyrimidine-8a-carboxylate [(+)-5]: White
crystals, (41% yield), m.p. 156–158 ◦C, [α]20D = +145 (c = 0.16, EtOH), ee 95%, 1H-NMR (600 MHz,
CDCl3, 30 ◦C): 2.46–2.52 (m, 1H, CH2), 2.70–2.74 (m, 1H, CH2), 2.83–2.98 (m, 2H, CH2), 3.82 (s, 3H,
OCH3), 3.96 (s, 3H, OCH3), 5.41 (d, J = 7.39 Hz, 1H, 3-H), 7.33 (d, J = 7.61 Hz, 1H, 4-H) 13C-NMR
(150 MHz, CDCl3, 30 ◦C): δ = 28.8, 30.0, 53.7, 66.0, 81.1, 104.7, 131.1, 165.5, 168.8, 170.6, HRMS calcd.
for [M + H+] m/z = 241.0825, found m/z = 241.0819.
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Methyl (S)-1-methoxy-2,6-dioxo-1,2,6,7,8,8a-hexahydropyrrolo[1,2-a]pyrimidine-8a-carboxylate [(–)-5]: White
crystals, (40% yield), m.p. 155–156 ◦C, [α]20D = −139 (c = 0.16, EtOH), ee 99% 1H- and 13C-NMR is
similar to (+)-5.
3.2.3. Synthesis of Methanopyrrolo[1,2-a]quinazoline Derivatives (+)-6a, (–)-6a, (+)-7a, and (–)-7a
A mixture of 2-aminonorbornene hydroxamic acid (+)-1, (–)-1, (+)-2, or (–)-2 (336 mg, 2 mmol) and
levulinic acid (232 mg, 2 mmol) was dissolved in 6 mL EtOH and heated in a 10 mL pressurized reaction
vial and the solution was stirred at 100 ◦C for 1 h at max 300 W microwave irradiation. After that the
reaction mixture was evaporated to dryness and the resulting oil was dissolved in dichloromethane
and was extracted with 15 mL 20% NaOH solution. The water phase was acidified with 20% HCl
solution and extracted with dichloromethane. The organic phase was dried (Na2SO4) and evaporated.
The gained yellow oil was dissolved in MeOH and a solution of diazomethane in Et2O was added in a
flask protected from light, at room temperature for about 30 min, until no starting material could be
observed by TLC. (Diazomethane is a very harmful and hazardous reagent and must be handled with
caution! This reaction should be performed in a well-ventilated hood!) The solvent was then removed
by evaporation and the residue was dissolved in EtOAc:MeOH = 9:1 (3 mL). The resulting solution
was transferred to a silica gel column and eluted with EtOAc:MeOH = 9:1 and the diastereomers were
separated. The products were crystallized from iPr2O to afford white crystals.
(3aR,5aS,6R,9S,9aR)-4-Methoxy-3a-methyl-2,3,3a,4,5a,6,9a-octahydro-6,9-methanopyrrolo[1,2-a]quinazoline-
1,5-dione [(+)-6a]: White crystals (29% yield), m.p. 158–161 ◦C, [α]20D = +23.1 (c = 0.44, EtOH), ee 99%,
1H-NMR (400 MHz, CDCl3, 30 ◦C): 1.39 (m, 1H, 11-H), 1.53 (s, 3H, CH3) 1.57–1.60 (m, 1H, 11-H),
2.12–2.16 (m, 2H, CH2), 2.38–2.44 (m, 2H, CH2), 3.00–3.04 (m, 1H, 5a-H), 3.45 (m, 1H, 9-H), 3.84 (s,
3H, OCH3), 4.03–4.06 (m, 1H, 9a-H), 4.11 (m, 1H, 6-H), 6.09–6.11 (m, 1H, 8-H), 6.18–6.20 (m, 1H, 7-H),
13C-NMR (100 MHz, CDCl3, 30 ◦C): δ = 23.9, 29.5, 30.8, 45.8, 46.4, 47.0, 48.6, 52.8, 64.8, 80.3, 135.3, 135.6,
170.8, 172.3, HRMS calcd. for [M + H+] m/z = 263.1396, found m/z = 263.1390.
(3aS,5aR,6S,9R,9aS)-4-Methoxy-3a-methyl-2,3,3a,4,5a,6,9a-octahydro-6,9-methanopyrrolo[1,2-a]quinazoline-
1,5-dione [(–)-6a]: White crystals (32% yield), m.p. 157–159 ◦C, [α]20D = −22.9 (c = 0.44, EtOH), ee 98%,
1H- and 13C-NMR is similar to (+)-6a.
(3aR,5aS,6S,9R,9aR)-4-Methoxy-3a-methyl-2,3,3a,4,5a,6,9a-octahydro-6,9-methanopyrrolo[1,2-a]quinazoline-
1,5-dione [(+)-7a]: White crystals, (28% yield), m.p. 141–142 ◦C, [α]20D = +62.3 (c = 1.12, EtOH), ee =87%,
1H-NMR (400 MHz, CDCl3, 30 ◦C): 1.61–1.64 (m, 1H, 11-H), 1.68 (m, 3H, CH3), 1.80–1.83 (m, 1H, 11-H),
2.17–2.33 (m, 2H, CH2), 2.42–2.55 (m, 2H, CH2), 2.60–2.63 (m, 1H, 5a-H), 2.81 (m, 1H, 9-H), 3.36 (m,
1H, 6-H), 3.91 (s, 3H, OCH3), 4.17–4.19 (m, 1H, 9a-H), 6.19–6.20 (m, 1H, 7-H), 6.39–6.41 (m, 1H, 8-H),
13C-NMR (100 MHz, CDCl3, 30 ◦C): δ = 22.9, 30.2, 31.3, 44.0, 45.0, 46.3, 48.5, 53.5, 65.3, 81.1, 136.5, 138.7,
166.4, 173.2, HRMS calcd. for [M + H+] m/z = 263.1396, found m/z = 263.1390.
(3aS,5aR,6R,9S,9aS)-4-Methoxy-3a-methyl-2,3,3a,4,5a,6,9a-octahydro-6,9-methanopyrrolo[1,2-a]quinazoline-
1,5-dione [(–)-7a]: White crystals, (31% yield), m.p. 138–141 ◦C = −72.3 (c = 1.18, EtOH), ee 91% 1H- and
13C-NMR is similar to (+)-7a.
3.2.4. Synthesis of Pyrrolo[1,2-a]pyrimidines (+)-8 and (–)-8
Tetracyclic compound (+)-6a, (+)-7a, (–)-6a, or (–)-7a (50 mg, 0.19 mmol) was dissolved in 2 mL
DCB in a 10 mL sealed reaction vial. The solution was stirred at 240 ◦C for 20 min at max 300 W
microwave irradiation. Then the solvent was evaporated, and the residue was dissolved in 2 mL
EtOAc and purified by column chromatography on silica gel eluted by EtOAc. The product was
crystallized from iPr2O to produce white crystals.
(S)-1-Methoxy-8a-methyl-1,7,8,8a-tetrahydropyrrolo[1,2-a]pyrimidine-2,6-dione [(+)-8]: White crystals, (55%
yield), m.p. 137–140 ◦C, [α]20D = +158 (c = 0.23, EtOH), ee 99 %, 1H-NMR (400 MHz, CDCl3, 30 ◦C): 1.49
(m, 3H, CH3), 2.37–2.46 (m, 2H, CH2), 2.51–2.69 (m, 2H, CH2), 3.89 (s, 3H, OCH3), 5.35 (d, J = 7.71 Hz,
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1H, 3-H), 7.31 (d, J = 7.62 Hz, 1H, 4-H), 13C-NMR (100 MHz, CDCl3, 30 ◦C): δ = 18.4, 30.0, 32.4, 65.5,
80.8, 104.3, 131.4, 166.3, 171.6, HRMS calcd. for [M + H+] m/z = 197.0926, measured: m/z = 197.0916.
(R)-1-methoxy-8a-methyl-1,7,8,8a-tetrahydropyrrolo[1,2-a]pyrimidine-2,6-dione[(–)-8]: White crystals, (57%
yield), m.p. 139–142 ◦C; [α]20D = –152 (c = 0.23, EtOH), ee 99%, 1H- and 13C-NMR is similar to (+)-8.
4. Conclusions
In conclusion, new racemic and enantiomeric pyrrolo[1,2-a]pyrimidines were synthesized starting
from diendo- and diexo-2-aminonorbornene hydroxamic acids. Their domino ring closure reactions
with α-ketoglutaric acid and levulinic acid, and the formation of two diastereomers were observed
in each case. After separation by column chromatography, single diastereomers were subjected
to a microwave-mediated RDA reaction and gained bicyclic pyrrolo[1,2-a]pyrimidines through the
loss of cyclopentadiene. When enantiomeric diexo- or diendo-3-amino-N-hydroxybicyclo[2.2.1]hept-
5-ene-2-carboxamides were used, the products were enantiomeric heterocycles with ee = 95–99%,
demonstrating that the starting compounds are excellent chiral sources, and the stereochemical
information can be effectively transferable to the newly formed stereogenic centre.
Supplementary Materials: Supplementary materials are available online.
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